JP2021169472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021169472A5 JP2021169472A5 JP2021111672A JP2021111672A JP2021169472A5 JP 2021169472 A5 JP2021169472 A5 JP 2021169472A5 JP 2021111672 A JP2021111672 A JP 2021111672A JP 2021111672 A JP2021111672 A JP 2021111672A JP 2021169472 A5 JP2021169472 A5 JP 2021169472A5
- Authority
- JP
- Japan
- Prior art keywords
- cebranopadol
- daily dose
- period
- dosing period
- dosing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CSMVOZKEWSOFER-RQNOJGIXSA-N cebranopadol Chemical compound C1([C@]2(CC[C@@]3(CC2)C2=C(C4=CC(F)=CC=C4N2)CCO3)N(C)C)=CC=CC=C1 CSMVOZKEWSOFER-RQNOJGIXSA-N 0.000 claims description 50
- 229950004621 cebranopadol Drugs 0.000 claims description 50
- 208000002193 Pain Diseases 0.000 claims description 8
- 230000002354 daily effect Effects 0.000 claims 50
- 239000003814 drug Substances 0.000 claims 15
- 230000002045 lasting effect Effects 0.000 claims 13
- 229940079593 drug Drugs 0.000 claims 5
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16157868.7 | 2016-02-29 | ||
| EP16157868 | 2016-02-29 | ||
| EP16020302 | 2016-08-11 | ||
| EP16020302.2 | 2016-08-11 | ||
| JP2018543634A JP7373904B2 (ja) | 2016-02-29 | 2017-02-28 | セブラノパドールの滴定 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543634A Division JP7373904B2 (ja) | 2016-02-29 | 2017-02-28 | セブラノパドールの滴定 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021169472A JP2021169472A (ja) | 2021-10-28 |
| JP2021169472A5 true JP2021169472A5 (https=) | 2022-11-08 |
Family
ID=58185482
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543634A Active JP7373904B2 (ja) | 2016-02-29 | 2017-02-28 | セブラノパドールの滴定 |
| JP2021111672A Pending JP2021169472A (ja) | 2016-02-29 | 2021-07-05 | セブラノパドールの滴定 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543634A Active JP7373904B2 (ja) | 2016-02-29 | 2017-02-28 | セブラノパドールの滴定 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11229625B2 (https=) |
| EP (1) | EP3423054A1 (https=) |
| JP (2) | JP7373904B2 (https=) |
| CN (2) | CN109069483A (https=) |
| AU (1) | AU2017226830B2 (https=) |
| BR (1) | BR112018017167A2 (https=) |
| CA (1) | CA3015420C (https=) |
| IL (1) | IL261133A (https=) |
| MX (1) | MX2018010367A (https=) |
| WO (1) | WO2017148595A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7373904B2 (ja) | 2016-02-29 | 2023-11-06 | パーク・セラピューティクス・インコーポレイテッド | セブラノパドールの滴定 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL348808A1 (en) * | 1998-11-02 | 2002-06-17 | Ortho Mcneil Pharm Inc | Analgesic regimen |
| US6339105B1 (en) * | 1999-10-12 | 2002-01-15 | Ortho-Mcneil Pharmaceutical, Inc. | Analgesic regimen |
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DK1572167T3 (da) | 2002-12-13 | 2008-10-13 | Euro Celtique Sa | Transdermal buprenophindoseringsbehandlingsplan for analgesi |
| US7413749B2 (en) | 2003-03-11 | 2008-08-19 | Purdue Pharma L.P. | Titration dosing regimen for controlled release tramadol |
| DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
| EP1985292A1 (en) | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
| WO2012016699A2 (en) | 2010-08-04 | 2012-02-09 | Grünenthal GmbH | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| KR20130097173A (ko) * | 2010-08-04 | 2013-09-02 | 그뤼넨탈 게엠베하 | 신경병증성 통증을 치료하기 위한 ６’플루오로（Ｎ메틸 또는 Ｎ，Ｎ디메틸）４페닐４’，９’디하이드로３’Ｈ스피로[사이클로헥산１，１’피라노[３，４，ｂ]인돌]４아민을 포함하는 약제학적 투여형 |
| WO2012016703A2 (en) | 2010-08-04 | 2012-02-09 | Grünenthal GmbH | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| AU2011287952B2 (en) | 2010-08-04 | 2014-08-21 | Grünenthal GmbH | Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane- 1,1'-pyrano[3,4,b]indol]-4-amine |
| EP2649044B1 (en) | 2010-12-08 | 2017-09-20 | Grünenthal GmbH | Method for synthesising substituted aminocyclohexanone derivatives |
| US8614245B2 (en) | 2011-07-08 | 2013-12-24 | Gruenenthal Gmbh | Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine |
| CN103649094B (zh) | 2011-07-08 | 2017-05-24 | 格吕伦塔尔有限公司 | 晶态的(1r,4r)‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺 |
| ES2605786T3 (es) | 2011-12-12 | 2017-03-16 | Grünenthal GmbH | Formas sólidas de clorhidrato de (1R,4R)-6'-fluor-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4b]indol]-4-amina |
| RS54960B1 (sr) | 2011-12-12 | 2016-11-30 | Gruenenthal Gmbh | Čvrsti oblici (1r,4r)-6'-fluoro-(n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-spiro-[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amina i sumporne kiseline |
| CN104159902B (zh) | 2011-12-12 | 2016-05-04 | 格吕伦塔尔有限公司 | 制备(1r,4r)-6’-氟-(N,N-二甲基-和N-甲基)-4-苯基-4’,9’-二氢-3’H-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的方法 |
| US20130310435A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US9308196B2 (en) | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
| US8912226B2 (en) | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
| US9320725B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| EP3110797B1 (en) | 2014-02-27 | 2018-08-29 | Grünenthal GmbH | Process for the preparation of 5-fluorotryptophol |
| JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
| JP7373904B2 (ja) | 2016-02-29 | 2023-11-06 | パーク・セラピューティクス・インコーポレイテッド | セブラノパドールの滴定 |
-
2017
- 2017-02-28 JP JP2018543634A patent/JP7373904B2/ja active Active
- 2017-02-28 CN CN201780013921.3A patent/CN109069483A/zh active Pending
- 2017-02-28 WO PCT/EP2017/025034 patent/WO2017148595A1/en not_active Ceased
- 2017-02-28 CN CN202410387184.5A patent/CN118286209A/zh active Pending
- 2017-02-28 BR BR112018017167A patent/BR112018017167A2/pt not_active IP Right Cessation
- 2017-02-28 AU AU2017226830A patent/AU2017226830B2/en not_active Expired - Fee Related
- 2017-02-28 CA CA3015420A patent/CA3015420C/en active Active
- 2017-02-28 EP EP17707471.3A patent/EP3423054A1/en not_active Withdrawn
- 2017-02-28 MX MX2018010367A patent/MX2018010367A/es unknown
-
2018
- 2018-08-13 IL IL261133A patent/IL261133A/en unknown
- 2018-08-29 US US16/116,055 patent/US11229625B2/en active Active
-
2021
- 2021-07-05 JP JP2021111672A patent/JP2021169472A/ja active Pending
- 2021-12-21 US US17/557,987 patent/US12161627B2/en active Active
-
2024
- 2024-10-31 US US18/933,387 patent/US20250255849A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010525050A5 (https=) | ||
| JP2018514534A5 (https=) | ||
| JP2022521233A5 (https=) | ||
| JP2024500324A5 (https=) | ||
| IL294736A (en) | Preparations including 15-hydroxy-eicosapentaenoic acid and methods of using them | |
| AU2009304002B2 (en) | A medicinal product and treatment | |
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| JP2025148449A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| KR101430089B1 (ko) | 류마티스 질환의 지연-방출형 글루코코르티코이드 치료제 | |
| IL307751B1 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| JP2021169472A5 (https=) | ||
| JP2022553888A5 (https=) | ||
| RU2181588C2 (ru) | Способ профилактики отсроченной рвоты | |
| JP2022177119A5 (https=) | ||
| JP2019535830A5 (https=) | ||
| Dotevall et al. | Controlled clinical trial of mepiprazole in irritable bowel syndrome | |
| JP2025511401A5 (https=) | ||
| JP2022504435A5 (https=) | ||
| JP2025522146A5 (https=) | ||
| JP2024531799A5 (https=) | ||
| JP2024506041A5 (https=) | ||
| CN104906501A (zh) | 治疗银屑病的中药组分组合物 | |
| Giovannoni et al. | 151. Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-month Results from the Phase 2 Open-Label Extension | |
| US20190381034A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases |